Ascletis Unveils ASC47 Weight Loss Drug Candidate
August 13, 2025 | 18:00
Preclinical data shows stronger muscle-preserving results than current leading treatments.
Ascletis presents new data on ASC30 and ASC47 at ADA 2025
June 09, 2025 | 13:00
Promising diabetes treatment results to be showcased at major U.S. scientific forum.
Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide
March 12, 2025 | 06:30
Ascletis Pharma Inc. announces encouraging pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies in Australia in healthy subjects with elevated low-density lipoprotein cholesterol (LDL-C) (Part I) and in patients with obesity (Part II) (NCT06427590).
Mobile Version